Drug manufacturer AstraZenecaAlexion’s rare diseases unit has signed an exclusive collaboration and licensing agreement with Neuro-immune which will see the pair develop and market NI006, an experimental human monoclonal antibody for the treatment of transthyretin amyloid cardiomyopathy.
AstraZeneca said on Friday that under the agreement Alexion will be granted an exclusive worldwide license to develop, manufacture and market NI006, with Neurimmune receiving an upfront payment of $ 30 million and the potential for additional milestone payments that may go up to $ 730.0 million, as well as as low to medium teenage royalties on the net sales of any approved drugs resulting from the collaboration.
The FTSE 100-rated group said there was “a significant unmet medical need” for patients with various types and levels of severity of amyloidosis who may require multiple mechanisms of action to address and that NI006, a depletor of ATTR, added a “new and complementary approach” to its pipeline of experimental therapies focused on amyloidosis and reinforced its “broader commitment to treat cardiomyopathies that can lead to heart failure”.
Alexion CEO Marc Dunoyer said: âWith 30 years of experience in drug development for people with rare diseases, Alexion is uniquely positioned to advance innovative science for small patient populations. that are often underdiagnosed.
“We look forward to applying this expertise to the development of NI006, which is designed to remove cardiac amyloid fibril deposits with the potential to improve cardiac function in patients living with advanced ATTR-CM, who are currently underserved by existing treatment options. “